1. Home
  2. CYN vs ICUCW Comparison

CYN vs ICUCW Comparison

Compare CYN & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYN
  • ICUCW
  • Stock Information
  • Founded
  • CYN 2013
  • ICUCW N/A
  • Country
  • CYN United States
  • ICUCW United States
  • Employees
  • CYN N/A
  • ICUCW 19
  • Industry
  • CYN EDP Services
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYN Technology
  • ICUCW Health Care
  • Exchange
  • CYN Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • CYN N/A
  • ICUCW N/A
  • IPO Year
  • CYN 2021
  • ICUCW 2021
  • Fundamental
  • Price
  • CYN $4.00
  • ICUCW $0.02
  • Analyst Decision
  • CYN
  • ICUCW
  • Analyst Count
  • CYN 0
  • ICUCW 0
  • Target Price
  • CYN N/A
  • ICUCW N/A
  • AVG Volume (30 Days)
  • CYN 24.2K
  • ICUCW N/A
  • Earning Date
  • CYN 08-06-2025
  • ICUCW N/A
  • Dividend Yield
  • CYN N/A
  • ICUCW N/A
  • EPS Growth
  • CYN N/A
  • ICUCW N/A
  • EPS
  • CYN N/A
  • ICUCW N/A
  • Revenue
  • CYN $409,777.00
  • ICUCW N/A
  • Revenue This Year
  • CYN $1,162.03
  • ICUCW N/A
  • Revenue Next Year
  • CYN $427.83
  • ICUCW N/A
  • P/E Ratio
  • CYN N/A
  • ICUCW N/A
  • Revenue Growth
  • CYN N/A
  • ICUCW N/A
  • 52 Week Low
  • CYN $3.62
  • ICUCW N/A
  • 52 Week High
  • CYN $1,600.50
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CYN 32.04
  • ICUCW N/A
  • Support Level
  • CYN $4.55
  • ICUCW N/A
  • Resistance Level
  • CYN $4.83
  • ICUCW N/A
  • Average True Range (ATR)
  • CYN 0.22
  • ICUCW 0.00
  • MACD
  • CYN -0.06
  • ICUCW 0.00
  • Stochastic Oscillator
  • CYN 0.00
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: